"In her World View, Beth Woods argues that a deal made with pharmaceutical giant Pfizer under US President Donald Trump's 'most-favoured nation' scheme, which aims to make drug prescriptions more affordable, is unlikely to work ()."
"I agree - but her own prescription might be equally ineffective."
"Competing Interests R.X. is a Senior Health Economist at RA Capital Management, which invests in public and private health-care and life-sciences companies developing drugs, medical devices, diagnostics, services and research tools."
Beth Woods contends that a Pfizer deal under President Trump's 'most-favoured nation' scheme, intended to make prescriptions more affordable, is unlikely to succeed. Agreement is expressed with that assessment while also warning that Woods's recommended alternative may be equally ineffective. The 'most-favoured nation' approach aims to achieve lower drug prices through pricing parity or negotiation mechanisms, but practical implementation and market responses raise doubts about its efficacy. A potential conflict of interest is disclosed: R.X. is a Senior Health Economist at RA Capital Management, which invests in a broad range of health-care and life-sciences companies.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]